These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12635130)

  • 1. The clinical evaluation of HER-2 status: which test to use?
    Bartlett J; Mallon E; Cooke T
    J Pathol; 2003 Apr; 199(4):411-7. PubMed ID: 12635130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
    Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
    Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.
    Sauter G; Lee J; Bartlett JM; Slamon DJ; Press MF
    J Clin Oncol; 2009 Mar; 27(8):1323-33. PubMed ID: 19204209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction.
    Kim MA; Jung EJ; Lee HS; Lee HE; Jeon YK; Yang HK; Kim WH
    Hum Pathol; 2007 Sep; 38(9):1386-93. PubMed ID: 17555797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Pathol Int; 2005 Jun; 55(6):318-23. PubMed ID: 15943788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
    Hicks DG; Tubbs RR
    Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.
    Dolan M; Snover D
    Am J Clin Pathol; 2005 May; 123(5):766-70. PubMed ID: 15981817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ; Jacobs TW
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables.
    Rasmussen BB; Andersson M; Christensen IJ; Møller S
    Acta Oncol; 2008; 47(4):784-8. PubMed ID: 18465349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of HER-2/neu in breast carcinoma].
    Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
    Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?
    Hameed O; Chhieng DC; Adams AL
    Am J Clin Pathol; 2007 Nov; 128(5):825-9. PubMed ID: 17951206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
    Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
    Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization.
    Graham AD; Faratian D; Rae F; Thomas JS
    Histopathology; 2008 Jun; 52(7):847-55. PubMed ID: 18494613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
    Prati R; Apple SK; He J; Gornbein JA; Chang HR
    Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quality control of HER2 immunohistochemistry--results from a Hungarian study].
    Cserni G; Kálmán E; Kulka J; Orosz Z; Udvarhelyi N; Krenács T
    Magy Onkol; 2007; 51(1):23-9. PubMed ID: 17417672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.